Member Info for serendipity

Kanabo refill cartridges have also been 'out of stock' on the British Cannabis website for months (link via the Kanabo group website). Alarm bells ringing...

I can't see how this is worth an MCAP of 16.67M and the Canadian charity given free shares are likely to be selling. IMO this has further to fall.

Legally, OBD can not email a single investor with market sensitive information. They can only repeat the information provided in a public RNS.

Don't be misled.

9.9M of that has only lasted 6 months, no wonder they are finding raising capital in the UK limited! The reduction in salaries is a smokescreen, BoD are getting paid to job hunt.

I believed in the products initially but not now, this would be a very cheap buyout for a top 10 Pharma company if they worked. IMO

I wouldn’t bet on it… oh sorry, you have

Hiving off means selling the US part of the company but they also state they ’ don’t envisage’ any offers for a takeover. I’m out.. this company is basically in administration IMO.. they’re doing a financial audit until January 2025, yeah right..

We didn't stand a chance against the Crick Institute and Royal Marsden Hospital tbh...

Hopefully UKRI will be able to confirm this funding with the new government within the original time frame.

Dug,

I disagree with your posts entirely but you’re entitled to your opinion, just like I’m entitled to mine. Good luck with your investment.

The tests on sale are validated.

I believe this study is great news for monitoring prostate cancer patients who have failed first line treatment/hormone therapy, usually monitored by PSA which is not a sensitive test.

IMO involvement in the TRANSFORM trial can happen at some point if appropriate, we don’t need it to sell PSE tests as they’re already available at the diagnostic stage.

Good to see PSE accessible to at least 27 Urologists who will order all tests available to private patients as the London clinic website is promoting PSE as a more accurate blood test than PSA. A positive step in my opinion.

@DugWalker

I am encouraged that Prof Ahmed is familiar with the PSE test.

Prof. Eeles is a very dynamic researcher who will want to investigate novel screening tests like PSE.

I hope that PSE will become a screening tool for prostate cancer diagnosis , patients on active surveillance and treatment monitoring.

Daily Mail interviewed Prof. Hashim Ahmed, chair of Urology at ICL about the TRANSFORM trial. He is also co-author on the PSE publications. Surely that's encouraging...

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17016

Positive results in my view.

Products are selling, increasing reach by opening 10 more walk in clinics by the end of the year, launch of products in Germany coming soon (distribution agreement in place) and a Treat It App all sounds exciting. DYOR

Let's hope Dr Dan Poulter helps this sector now that he has defected to the Labour party...

Very disappointed that it seems there's no plan to launch Eroxon in the US this year. I'm also concerned that the EU patent protection for Eroxon may not be robust for all markets.

I'm out, for now anyway..

His holding before fund raise = 6,603,082 shares

333,333 shares purchased in the fundraise

New total = 6,936,415 shares, 2.2% of the company after fundraising shares admitted on Monday.

No shares sold as far as I can see.

No shares have been sold.

Read the last 2 RNS releases and check the names and numbers for yourself.

UK Customers can now get Eroxon on NHS prescription, so OTC sales may appear to drop but this isn’t likely to be the case. Coopers and Haleon will be able to analyse demand through NHS contracts, which is highly significant in my view.